Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A compound for modulating c-Kit activity according to Formula I,

or a pharmaceutically acceptable salt, thereof, wherein,

ring A is:

	(R ¹) ₀₋₃ (R ¹)	$(R^1)_{0-3}$
X	$\{\begin{array}{c} Z \\ \frac{1}{ I } \\ N - \sqrt{N} \\ (R^1)_{0-2} \end{array}\}$	$(R^1)_{0-1}$
(R ¹) ₀₋₁	Z	Z N II (R ¹) ₀₋₁
(R ¹) ₀₋₄	$(R^1)_{0-5}$ Z Z Y Y	$(R^1)_{0-5}$
(R ¹) ₀₋₆ Z	(R ¹) ₀₋₆ Y	(R ¹) ₀₋₆ Y Y Y

- wherein each Y is independently either =C(H)- or =N-; and Z is selected from -O-, -S-, and- $N(R^7)$ -, provided that the A ring contains at least one annular N, O, or S;
- each R^1 is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- two adjacent of R¹, together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R¹⁰;

L¹ is a single bond;

ring B is phenyl;

- each R^2 is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- two adjacent of R^2 , together with the annular atoms to which they are attached, can form a five- to six-membered ring containing up to two heteroatoms and optionally substituted with up to three of R^{15} ;
- L^2 is selected from -N(H)N(H)C(=O)N(H)-, -CH₂N(H)C(=O)N(H)-, -CH₂OC(=O)N(H)-, and -XCH₂C(=O)N(H)-; wherein X is selected from -O-, -S(O)₀₋₂-, and -N(R⁷)-; and any C-H of L^2 is optionally C-R²⁰;

ring C is phenyl;

each R³ is independently selected from halogen, trihalomethyl, -CN,

-NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl; provided R^3 is not a cyclic sulfonamide attached to ring C via the nitrogen of said cyclic sulfonamide,

wherein there exists at least one of R³ that is halogen or trihalomethyl;

- R^4 is selected from -H, optionally substituted $C_{1\text{-}6}$ alkyl, optionally substituted aryl, optionally substituted aryl $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl;
- two of R⁴, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;
- R^5 is selected from -H, -CN, -NO₂, -OR⁴, -S(O)₀₋₂R⁴, -CO₂R⁴, optionally substituted $C_{1\text{-}6}$ alkyl, optionally substituted $C_{1\text{-}6}$ alkenyl, and optionally substituted $C_{1\text{-}6}$ alkynyl;
- R^7 is selected from -H, optionally substituted $C_{1\text{-}6}$ alkyl, -SO₂N(R^4) R^4 , -CO₂ R^4 , -C(=O)N(R^4) R^4 , -C(=N R^5)N(R^4) R^4 , -C(=N R^5)R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted aryl $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl; and
- each of R^{10} , each of R^{15} , each of R^{20} , and each of R^{25} is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴, -N(R⁴)R⁴, -S(O)₀₋₂R⁴, -SO₂N(R⁴)R⁴, -CO₂R⁴, -C(=O)N(R⁴)R⁴, -C(=NR⁵)N(R⁴)R⁴, -C(=NR⁵)R⁴, -N(R⁴)SO₂R⁴, -N(R⁴)C(O)R⁴, -NCO₂R⁴, -C(=O)R⁴, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl

 $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl;

provided:

; and

the compound is not one of:

N-(2,3-dichlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide,

N-(4-chloro-3-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide,

N-(4-bromophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide

N-(2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide

N-(4-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide

2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}-N-[2-(trifluoromethyl)phenyl]acetamide

2-{[3-(1H-tetrazol-1-yl)phenyl] oxy}-N-[3-(trifluoromethyl)phenyl]acetamide

N-[2-chloro-5-(trifluoromethyl) phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide

N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{[3-(4H-1,2,4-triazol-4-yl)phenyl]oxy} acetamide or

N-(4-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide.

2-12. (Cancelled)

- 13. (Previously presented) The compound according to claim 1, wherein there exists at least one of R³ that is trifluoromethyl.
- 14. (Original) The compound according to claim 13, wherein ring C is a phenyl comprising a trifluoromethyl radical meta- to L^2 .
- 15. (Previously presented) The compound according to claim 1, wherein each of R^3 is independently selected from halogen, trihalomethyl, $-OR^4$, $-C(=O)R^4$, and optionally substituted C_{1-6} alkyl.
- 16. (Currently amended) A compound for modulating c-Kit activity according to the following Formula:

$$(R^{26})_{0-4}$$
 E^{-G}
 H
 H
 H
 H
 H
 H

or a pharmaceutically acceptable salt, thereof, wherein,

W is selected from the following:

	(R ²⁷) ₀₋₃	$(R^{27})_{0-3}$
Z	Z	$(R^{27})_{0-1}$
$(\mathbb{R}^{27})_{0-1}$	$ \begin{array}{c c} Z & \overline{\parallel} \\ \hline $	Z N
(R ²⁷) ₀₋₄ Y—Y	$(R^{27})_{0-5}$ X Z	(R ²⁷) ₀₋₅ Y Y Y Z Z Y
(R ²⁷) ₀₋₆ Z Y Y Y Y	(R ²⁷) ₀₋₆	$(R^{27})_{0-6} \xrightarrow{\overset{\checkmark}{}} \overset{\overset{\checkmark}{}}{\overset{\checkmark}{}} \overset{\overset{\checkmark}{}}{\overset{\checkmark}{}} \overset{\overset{\checkmark}{}}{\overset{\checkmark}{}} \overset{\overset{\checkmark}{}}{}}$

each of R^{27} independently selected from halogen, trihalomethyl, -CN, -NO₂, -OR⁵⁵, -S(O)₀₋₂R⁵⁵, -SO₂N(R⁵⁵)R⁵⁵, -C(=O)N(R⁵⁵)R⁵⁵, -C(=NR⁵⁰)N(R⁵⁵)R⁵⁵, -C(=NR⁵⁰)R⁵⁵, -N(R⁵⁵)SO₂R⁵⁵, -N(R⁵⁵)C(O)R⁵⁵, -NCO₂R⁵⁵, -C(=O)R⁵⁵, optionally substituted alkoxy, optionally substituted $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl;

each Y is independently either =C(H)- or =N-;

Z is selected from -O-, -S(O)₀₋₂-, and -N(\mathbb{R}^7)-,

provided that the W ring contains at least one annular annular N, O, or S;

E and G are each independently selected from -O-, -S(O)₀₋₂-, -C(R³¹)R³²-, and -N(R³³)-; J_1 and J_2 are each independently =C(H)- or =N-;

- R^{26} is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -S(O)₀₋₂R⁴⁰, -SO₂N(R⁴⁰)R⁴⁰, -CO₂R⁴⁰, -C(=O)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)R⁴⁰, -N(R⁴⁰)SO₂R⁴⁰, -N(R⁴⁰)C(O)R⁴⁰, -NCO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- R^{30} is independently selected from halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -S(O)₀₋₂R⁴⁰, -SO₂N(R⁴⁰)R⁴⁰, -C(=O)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)R⁴⁰, -N(R⁴⁰)SO₂R⁴⁰, -N(R⁴⁰)C(O)R⁴⁰, -NCO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl, wherein there exists at least one of R^{30} that is trihalomethyl;
- R^{31} and R^{32} are each independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -OR⁴⁰, -N(R⁴⁰)R⁴⁰, -S(O)₀₋₂R⁴⁰, -SO₂N(R⁴⁰)R⁴⁰, -CO₂R⁴⁰, -C(=O)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)N(R⁴⁰)R⁴⁰, -C(=NR⁵⁰)R⁴⁰, -N(R⁴⁰)SO₂R⁴⁰, -N(R⁴⁰)C(O)R⁴⁰, -NCO₂R⁴⁰, -C(=O)R⁴⁰, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl;
- R^{33} is selected from -H, optionally substituted lower alkyl, $-SO_2N(R^{40})R^{40}$, $-CO_2R^{40}$, $-C(=O)N(R^{40})R^{40}$, $-C(=NR^{50})N(R^{40})R^{40}$, $-C(=NR^{50})R^{40}$, $-C(=O)R^{40}$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted heterocyclyl C_{1-6} alkyl;

- R^{40} is selected from -H, optionally substituted alkoxy, optionally substituted $C_{1\text{-}6}$ alkyl, optionally substituted aryl $C_{1\text{-}6}$ alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl $C_{1\text{-}6}$ alkyl;
- two of R⁴⁰, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P;
- R^{50} is selected from -H, -CN, -NO₂, -OR⁴⁰, -S(O)₀₋₂R⁴⁰, -CO₂R⁴⁰, optionally substituted $C_{1\text{-}6}$ alkyl, optionally substituted $C_{1\text{-}6}$ alkenyl, and optionally substituted $C_{1\text{-}6}$ alkynyl;
- R^{55} is selected from -H, optionally substituted C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl; and
- two of R⁵⁵, when taken together with a common nitrogen to which they are attached, form an optionally substituted five- to seven-membered heterocyclyl, said optionally substituted five- to seven-membered heterocyclyl optionally containing at least one additional heteroatom selected from N, O, S, and P.
- 17. (Cancelled)
- 18. (Previously presented) The compound according to claim 16, wherein R^{30} is selected from halogen, trihalomethyl, $-OR^{40}$, $-N(R^{40})R^{40}$, $-C(=O)R^{40}$, optionally substituted alkoxy, optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted aryl C_{1-6} alkyl, optionally substituted heterocyclyl, and optionally substituted heterocyclyl C_{1-6} alkyl, wherein there exists at least one of R^{30} that is trifluoromethyl.
- 19. (Cancelled)
- 20. (Cancelled)
- 21. (Cancelled)
- 22. (Cancelled)

- 23. (Withdrawn) The compound according to claim 16, wherein E is selected from -O-, $-S(O)_{0-2}$ -, and -NH-; and G is -CH₂-.
- 24. (Withdrawn) The compound according to claim 16, wherein E is either -CH₂- or -NH-; and G is selected from -O-, -S-, and -NH-.
- 25. (Cancelled)
- 26. (Cancelled)
- 27. (Previously presented) A compound selected from the following Table:

Entry	Name	Structure
1	N-[5-chloro-2-(methyloxy)phenyl]-2-{[3- (1H-tetrazol-1-yl)phenyl]oxy}acetamide	CH ₃ O N N N N N N N N N N N N N N N N N N
4	N-(2-chlorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	
5	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N N N N N N N N N N N N N N N N N N N
7	N-(3-chloro-2-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N = N CH ₃ CI

Entry	Name	Structure
8	N-(3-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	Name of the second seco
9	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2H-tetrazol-5- yl)phenyl]oxy}acetamide	N N CI
10	N-(4-chloro-2-fluorophenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N. N. N. D. O. N. H. F.
11	N-(4-bromo-3-methylphenyl)-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N. N. N. CH ₃
13	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N. N

Entry	Name	Structure
14	N-[4-bromo-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	TZ-ZZ
15	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CI F F F F
16	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	CH ₃ H C ₁ C ₁ C ₁ C ₁
17	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(5-methyl-1H-tetrazol-1- yl)phenyl]oxy}acetamide	N CH ₃ O N F F
18	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-methyl-5-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	CH ₃ F F CI

Entry	Name	Structure
19	N-(4-chlorophenyl)-N-methyl-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide	N, N CH ₃
20	N-[4-chloro-2-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N-N-N-O-N-F-F
23	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	NN.N NN.N FF FF
24	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(2-methyl-2H-tetrazol-5- yl)phenyl]oxy}acetamide	H ₃ C FFF
25	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,4-dichloro-5-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	
26	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]thio}acetamide	N. N. S. N. F.

Entry	Name	Structure
27	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	P P P P P P P P P P P P P P P P P P P
28	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	ON H F F
37	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyridin-4-ylphenyl)oxy]acetamide	N O N F F F
38	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-methyl-N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	CH ₃ O CH ₃ O CI F F F F
49	N-[5-chloro-2,4-bis(methyloxy)phenyl]-2- {[3-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	N.N. N HOCH3

Entry	Name	Structure
52	N-[2-(methyloxy)-5- (trifluoromethyl)phenyl]-2-{[3-(1H- tetrazol-1-yl)phenyl]oxy}acetamide	N.N. N. H. F.
57	1,1-dimethylethyl 2-{3-[(2-{[4-chloro-3- (trifluoromethyl)phenyl]amino}-2- oxoethyl)oxy]phenyl}-1H-pyrrole-1- carboxylate	TO NOTE OF F
58	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-pyrrol-2-yl)phenyl]oxy}acetamide	CI PFF FF
59	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyrimidin-5-ylphenyl)oxy]acetamide	N O N F F F
60	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(1H-1,2,3-triazol-1- yl)phenyl]oxy}acetamide	N. N. P. F.

Entry	Name	Structure
63	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-pyridin-3-ylphenyl)oxy]acetamide	O N F F F
68	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-(3,5-dimethylisoxazol-4- yl)phenyl]oxy}acetamide	H_3C CH_3 CH_3
69	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(3-quinolin-7-ylphenyl)oxy]acetamide	ON FFFF
71	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [3-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	N. N. H. H. F.
73	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyrimidin-5-ylphenyl)oxy]acetamide	N F F F CI

Entry	Name	Structure
75	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(1H-tetrazol-1-yl)phenyl]methyl}urea	N N N N N N N N N N N N N N N N N N N
77	N-[4-fluoro-3-(trifluoromethyl)phenyl]- N~2~-[3-(1H-tetrazol-1- yl)phenyl]glycinamide	NN=N NN=N NN=N NN=N NN=N NN=N NN=N NN=
79	N-[2-fluoro-5-(trifluoromethyl)phenyl]-2- [3-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	N N N N N N N N N N N N N N N N N N N
80	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	ON H F F
81	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyrimidin-5-ylphenyl)methyl]urea	N N N N N N N N N N N N N N N N N N N
82	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyrimidin-5-ylphenyl)methyl]urea	N N N F F F

Entry	Name	Structure
83	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	N N F F F
84	[3-(1H-tetrazol-1-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	N. N. N. P. F.
85	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyrimidin-5-ylphenyl)oxy]acetamide	N H F F
86	N~2~-[4-chloro-3- (trifluoromethyl)phenyl]-N-[3-(1H- tetrazol-1-yl)phenyl]glycinamide	N. N. H. H. F. F. F.
87	2-{[4-chloro-3- (trifluoromethyl)phenyl]oxy}-N-[3-(1H- tetrazol-1-yl)phenyl]acetamide	N.N.N. H. CI N.N.N. F. F. F.

Entry	Name	Structure
88	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-methyl-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	H ₃ C CI N=N
89	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-1,2,3-triazol-1- yl)phenyl]oxy}acetamide	CI F F F
90	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[3-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	F CI N=N
91	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2-fluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	P CI F F F F
94	N-[4-fluoro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-3-ylphenyl)oxy]acetamide	O N F F F

Entry	Name	Structure
95	2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-N-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide	H ₃ C ₂ O _N F _F F
96	2-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}oxy)-N-[4-chloro-3-(trifluoromethyl)phenyl]acetamide	H ₃ C ₂ O ₁ O ₁ O ₁ O ₂ O ₁ O ₂ O ₃ O ₄ O ₄ O ₅ O ₅ O ₅ O ₆ O ₆ O ₇
97	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [(4-pyridin-4-ylphenyl)oxy]acetamide	ON H F F
98	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(methyloxy)-4-(1H-tetrazol-1- yl)phenyl]glycinamide	H ₃ C ² O H O H F F F F
99	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[4-(methyloxy)-3-(1H-tetrazol-1- yl)phenyl]glycinamide	N N N H P F F F

Entry	Name	Structure
100	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[4-(1H-tetrazol-1- yl)phenyl]glycinamide	CI F N N=N
101	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (2,3,5,6-tetrafluoro-4-pyrimidin-5- ylphenyl)hydrazinecarboxamide	F H N N H F F
102	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(1H-tetrazol-1-yl)phenyl]methyl}urea	ON PER
103	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyrimidin-5- ylphenyl)hydrazinecarboxamide	H. N. N. N. P. F.
104	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyridin-3-ylphenyl)methyl]urea	N N N F F F

Entry	Name	Structure
105	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- methyl-2-{[3-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	N. N. N. P. F.
106	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-tetrazol-1- yl)phenyl]oxy}propanamide	CI FFF CH ₃
107	N-({4-[2,4-bis(methyloxy)pyrimidin-5-yl]phenyl}methyl)-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₃ C ₁ C ₁ H ₃ C ₁
108	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[2-(methyloxy)pyrimidin-5- yl]phenyl}methyl)urea	H ₃ C ² O N O CI F F F F
109	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[6-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C'O

Entry	Name	Structure
110	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[2-(methyloxy)pyrimidin-5- yl]phenyl}methyl)urea	H ₃ C ₂ O N N P F F
111	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[6-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C ₂ O _N
114	N-[4-chloro-3-(trifluoromethyl)phenyl]- N~2~-[3-(2H-tetrazol-5- yl)phenyl]glycinamide	N=N HN.N
115	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[2,6-difluoro-4-(1H-tetrazol-1- yl)phenyl]oxy}acetamide	F F F
116	(3-pyridin-3-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	O N F F F

Entry	Name	Structure
117	(3-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	N CI F F F
118	(3-pyridin-4-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N CI P F F
119	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- [4-(1H-tetrazol-1- yl)phenyl]hydrazinecarboxamide	TH. NH. PF. F
120	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyridin-3- ylphenyl)hydrazinecarboxamide	H. N. H. F. F. F.
121	(4-pyridin-3-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	ON FFFF

Entry	Name	Structure
122	(4-pyridin-4-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	ON PERSONAL PROPERTY OF THE PR
123	(4-pyrimidin-5-ylphenyl)methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	N CI N F F
124	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-4-ylphenyl)methyl]urea	N N N F F
125	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyridin-3- ylphenyl)hydrazinecarboxamide	H N H F F
126	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyrimidin-5- ylphenyl)hydrazinecarboxamide	N N N N N N N N N N N N N N N N N N N

Entry	Name	Structure
127	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(4-pyrimidin-5-ylphenyl)methyl]urea	N H O CH3
128	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(4-pyridin-3-ylphenyl)methyl]urea	N N O CH ₃
129	(4-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate	O H O CH ₃
130	(4-pyridin-3-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	ON CH3
131	1-(4-pyridin-3-ylphenyl)ethyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	CH ₃ O N F F

Entry	Name	Structure
132	1-(4-pyrimidin-5-ylphenyl)ethyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	CH ₃ O N F F
133	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(3-pyridin-3-ylphenyl)methyl]urea	N O CH ₃
134	N-[5-chloro-2,4-bis(methyloxy)phenyl]- N'-[(3-pyrimidin-5-ylphenyl)methyl]urea	N O CH ₃
135	(3-pyridin-3-ylphenyl)methyl [5-chloro- 2,4-bis(methyloxy)phenyl]carbamate	N O CH ₃
136	(3-pyrimidin-5-ylphenyl)methyl [5-chloro-2,4-bis(methyloxy)phenyl]carbamate	N CI CCH ₃

Entry	Name	Structure
138	N-[4-fluoro-3-(trifluoromethyl)phenyl]-N'- [(4-pyridin-3-ylphenyl)methyl]urea	N N N F F F
143	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [1-(4-pyridin-3-ylphenyl)ethyl]urea	CH ₃ O CI P F F
144	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [1-(4-pyrimidin-5-ylphenyl)ethyl]urea	CH ₃ O CI F F F
145	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(1H-indol-2-yl)phenyl]oxy}acetamide	ON THE F
147	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (4-pyridin-4- ylphenyl)hydrazinecarboxamide	TH. NH. PH. F.

Entry	Name	Structure
148	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- (3-pyridin-4- ylphenyl)hydrazinecarboxamide	ZH Z
149	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-pyridin-4-ylphenyl)methyl]urea	N N N N N N N N N N N N N N N N N N N
150	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-quinoxalin-6-ylphenyl)methyl]urea	N CI F F F
152	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-quinoxalin-6-ylphenyl)methyl]urea	N N N F F F
155	[3-(1H-tetrazol-1-yl)phenyl]methyl [3-chloro-4-(methyloxy)phenyl]carbamate	N CI N CH ₃

Entry	Name	Structure
156	N-[3-chloro-4-(methyloxy)phenyl]-N'-{[3-(1H-tetrazol-1-yl)phenyl]methyl}urea	N CH ₃
157	N-[4-chloro-3-(trifluoromethyl)phenyl]-2- {[4-(5-hydroxy-1H-tetrazol-1- yl)phenyl]oxy}acetamide	HO N F F
160	N-{[3-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N N N N N N N N N N N N N N N N N N N
161	N-{[4-(6-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N H H F F
165	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-fluoropyridin-3- yl)phenyl]methyl}urea	F N CI F F F

Entry	Name	Structure
166	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[2-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	H ₃ C.O
167	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(6-fluoropyridin-3- yl)phenyl]methyl}urea	F N P F F
168	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({4-[2-(methyloxy)pyridin-3- yl]phenyl}methyl)urea	N H H F F F F F F F F F F F F F F F F F
169	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(6-methylpyridin-3- yl)phenyl]methyl}urea	H ₃ C N
171	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-methylpyridin-3- yl)phenyl]methyl}urea	H ₃ C CI N H H F F

Entry	Name	Structure
174	[3-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	H ₃ C CI F F F F
177	(3-pyrazin-2-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N O N F F F
179	N-{[3-(6-acetylpyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	H ₃ C N CF ₃
180	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(6-cyanopyridin-3- yl)phenyl]methyl}urea	NC N O CI N N N CF3
185	[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN P F F
188	[3-(1H-benzimidazol-2-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	N N N N N N F F F

Entry	Name	Structure
190	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[5-(methylthio)pyridin-3- yl]phenyl}methyl)urea	S CH ₃ CF ₃
191	[4-(6-methylpyridin-3-yl)phenyl]methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	H ₃ C N
194	(4-pyrazin-2-ylphenyl)methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	ON H F F F
195	[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN H F F F
200	(3-pyridin-3-ylphenyl)methyl [5-chloro-2- (methyloxy)phenyl]carbamate	CH ₃ ON N

Entry	Name	Structure
201	[4-(1H-tetrazol-1-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	ON H F F
202	(3-pyrimidin-5-ylphenyl)methyl [5-chloro-2-(methyloxy)phenyl]carbamate	CH ₃ O N CH CI
213	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(1H-pyrazol-4-yl)phenyl]methyl}urea	N N N CF ₃
214	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(1H-pyrazol-4-yl)phenyl]methyl}urea	HN CF3
215	[3-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	HN N N CF ₃

Entry	Name	Structure
216	[4-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	CF ₃ CI
217	N-{[3-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	N CI O CF ₃
218	N-{[4-(2-chloropyridin-3-yl)phenyl]methyl}-N'-[4-chloro-3-(trifluoromethyl)phenyl]urea	CI N CF3
219	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[3-(2-fluoropyridin-3- yl)phenyl]methyl}urea	P CF ₃
220	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- {[4-(2-fluoropyridin-3- yl)phenyl]methyl}urea	N N CF3

Entry	Name	Structure
221	[3-(1H-tetrazol-1-yl)phenyl]methyl [3- (trifluoromethyl)phenyl]carbamate	N N N H F F
224	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- ({3-[5-(methylthio)pyridin-2- yl]phenyl}methyl)urea	H ₃ C ^{-S} N O CF ₃
225	[3-(2,6-dimethylpyridin-3-yl)phenyl]methyl [4-chloro-3-(trifluoromethyl)phenyl]carbamate	H ₃ C CF ₃
226	{3-[5-(methyloxy)pyridin-3- yl]phenyl}methyl [4-chloro-3- (trifluoromethyl)phenyl]carbamate	Or CH ₃ Or CH ₃ Or CH ₃ CF ₃
229	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(3-isoquinolin-4-ylphenyl)methyl]urea	N N CF ₃

Entry	Name	Structure
230	N-[4-chloro-3-(trifluoromethyl)phenyl]-N'- [(4-isoquinolin-4-ylphenyl)methyl]urea	O N N C F S
232	[3-(1H-pyrazol-4-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	ON PER F
233	[4-(1H-pyrazol-4-yl)phenyl]methyl [4- chloro-3- (trifluoromethyl)phenyl]carbamate	HNN FF

- 28. (Previously presented) A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
- 29. (Cancelled)
- 30. (Withdrawn) A method for modulating the *in-vivo* activity of a kinase, the method comprising administering to a subject an effective amount of the compound according to claim 1.
- 31. (Withdrawn) The method according to claim 30, wherein the kinase is c-Kit.
- 32. (Withdrawn) The method according to claim 31, wherein modulating the *in vivo* activity of c-Kit comprises inhibition of c-Kit.
- 33. (Withdrawn) A method of treating rheumatoid arthritis, graft-host diseases, multiple sclerosis, psoriasis; artheroscrosis, myocardioinfarction, ischemia, stroke, restenosis; interbowel diseases, osteoarthritus, macular degeneration, or diabetic retinopathy, the method comprising administering, to a mammal in need thereof, a therapeutically

effective amount of the compound or the pharmaceutical composition as described in claim 1 .

- 34. (Withdrawn) A method of screening for modulators of c-Kit, the method comprising combining the compound according to claim 1 and at least one candidate agent and determining the effect of the candidate agent on c-Kit activity.
- 35. (Withdrawn) A method of inhibiting proliferative activity in a cell, the method comprising administering an effective amount of a composition comprising the compound according to claim 1 to a cell or a plurality of cells.